Clinical Trial

A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia

Completed
View on ClinicalTrials.gov →
Summary
The aim of this study was to investigate the safety, tolerability, and effectiveness of eltrombopag in combination with immunosuppressive therapy (IST) in real world practice in pediatric patients with severe aplastic anemia (sAA) in Korea. The study used data over a 6-month period extracted from patients' medical charts (electronic medical records) starting from the initiation of eltrombopag treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-11.
Trial Details
NCT Number NCT07415083
Lead Sponsor Novartis Pharmaceuticals
Conditions Aplastic Anemia
Enrollment 13 participants
Start Date 2023-06-21
Primary Completion 2025-02-25 (estimated)
Study Completion 2025-02-25 (estimated)
Updated on ClinicalTrials.gov 2026-02-19